Results 311 to 320 of about 118,448 (336)

Switching and combining of dopamine agonists [PDF]

Journal of Neurology, 2004
Dopamine agonists have been proved safe and effective as initial therapy in early stages of Parkinson's disease. Prospective long-term clinical trials demonstrated that initial symptomatic treatment with a dopamine agonist is associated with a significantly reduced risk for motor complications in comparison with levodopa therapy.
Theresa Glöckler, Heinz Reichmann, S. Junghanns   +2 more
openaire   +2 more sources

Alopecia induced by dopamine agonists [PDF]

Neurology, 2002
We report two women with PD who developed alopecia while being treated with the dopamine agonists pramipexole and ropinirole. The alopecia reversed partially after the drugs were discontinued. Both women were postmenopausal and had no history of hair loss or other dermatologic disorders.
Rowena E. Tabamo, Alessandro Di Rocco
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Dopamine and dopamine receptor agonists in cardiovascular therapy

Critical Care Medicine, 1990
Dopamine (DA)--previously regarded simply as the precursor of norepinephrine--is now known to have its own unique effects on cardiovascular regulation which are mediated, in part, by activating specific DA receptors. DA has long been used in the treatment of shock and heart failure.
Michael B. Murphy, William J. Elliott
openaire   +3 more sources

Switching and combining dopamine agonists

Journal of Neural Transmission, 2003
Switching from one dopamine agonist to another is common practice in the treatment of patients with Parkinson's disease. This paper describes some ideas on the most practical way to perform switching. In addition, it describes the possibilities of combining various dopamine agonists and discusses pros and cons for doing so.
B. Herting, A. Mïller, Heinz Reichmann, U. Sommer   +3 more
openaire   +3 more sources

Ropinirole hydrochloride, a dopamine agonist

Acta Crystallographica Section C Crystal Structure Communications, 2006
Ropinirole hydrochloride, or diethyl[2-(2-oxo-2,3-dihydro-1H-indol-4-yl)ethyl]ammonium chloride, C16H25N2O+.Cl-, belongs to a class of new non-ergoline dopamine agonists which bind specifically to D2-like receptors with a selectivity similar to that of dopamine (D3 > D2 > D4).
Krishnan Ravikumar, Balasubramanian Sridhar   +1 more
openaire   +3 more sources

Dopamine: Agonists and Neurodegenerative Disorders

Current Drug Targets, 2018
Parkinson's disease (PD) is a neurodegenerative disease characterized by the loss of dopaminergic neurons within the substantia nigra pars compacta (SNpc). Despite many researches, there is still no cure for this disease. Levodopa is the first line treatment of PD, but the long term use of it leads to motor impairments and dyskinesias.
Yasir Hasan Siddique, Saba Khanam
openaire   +3 more sources

Dopamine agonists in Parkinson’s disease

Expert Review of Neurotherapeutics, 2008
Dopamine agonists are established as effective drugs for the symptomatic treatment of Parkinson's disease (PD) throughout its course. As monotherapy, they produce effective control of motor symptoms and combine this with a low risk for motor complications.
Mitsutoshi Yamamoto, Anthony H.V. Schapira   +1 more
openaire   +3 more sources

Treatment of Acromegaly with Dopamine Agonists

Endocrinology and Metabolism Clinics of North America, 1992
This article reviews the current understanding of how dopamine agonists stimulate growth hormone secretion in normal individuals, yet suppress growth hormone secretion in acromegaly patients. Although bromocriptine normalizes growth hormone or somatomedin C hypersecretion in a minority of patients, a significant number of subjects have a clinical ...
Craig A. Jaffe, Ariel L. Barkan
openaire   +3 more sources

Clinical Pharmacology of Dopamine Agonists

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2000
With the availability of newer dopamine agonists selective for dopamine (D2) receptor subtypes, medical management of Parkinson's disease has progressed substantially. These agents can decrease the frequency of ergot‐related side effects and dyskinesias.
openaire   +3 more sources

Dopamine agonists and therapy compliance

Neurological Sciences, 2008
Dopamine replacement therapy in Parkinson's disease improves motor symptoms, however some patients suffer from motor and behavioural disturbances attributable to taking doses of medication well beyond the dose required to treat their motor disabilities.
openaire   +3 more sources